Lithium therapy improves neurological function and hippocampal dendritic arborization in a spinocerebellar ataxia type 1 mouse model
Kei Watase, Jennifer R Gatchel, Yaling Sun, Effat Emamian, Richard Atkinson, Ronald Richman, Hidehiro Mizusawa, Harry T Orr, Chad Shaw, Huda Y Zoghbi, Kei Watase, Jennifer R Gatchel, Yaling Sun, Effat Emamian, Richard Atkinson, Ronald Richman, Hidehiro Mizusawa, Harry T Orr, Chad Shaw, Huda Y Zoghbi
Abstract
Background: Spinocerebellar ataxia type 1 (SCA1) is a dominantly inherited neurodegenerative disorder characterized by progressive motor and cognitive dysfunction. Caused by an expanded polyglutamine tract in ataxin 1 (ATXN1), SCA1 pathogenesis involves a multifactorial process that likely begins with misfolding of ATXN1, which has functional consequences on its interactions, leading to transcriptional dysregulation. Because lithium has been shown to exert neuroprotective effects in a variety of conditions, possibly by affecting gene expression, we tested the efficacy of lithium treatment in a knock-in mouse model of SCA1 (Sca1(154Q/2Q) mice) that replicates many features of the human disease.
Methods and findings: Sca1(154Q/2Q) mice and their wild-type littermates were fed either regular chow or chow that contained 0.2% lithium carbonate. Dietary lithium carbonate supplementation resulted in improvement of motor coordination, learning, and memory in Sca1(154Q/2Q) mice. Importantly, motor improvement was seen when treatment was initiated both presymptomatically and after symptom onset. Neuropathologically, lithium treatment attenuated the reduction of dendritic branching in mutant hippocampal pyramidal neurons. We also report that lithium treatment restored the levels of isoprenylcysteine carboxyl methyltransferase (Icmt; alternatively, Pccmt), down-regulation of which is an early marker of mutant ATXN1 toxicity.
Conclusions: The effect of lithium on a marker altered early in the course of SCA1 pathogenesis, coupled with its positive effect on multiple behavioral measures and hippocampal neuropathology in an authentic disease model, make it an excellent candidate treatment for human SCA1 patients.
Conflict of interest statement
Competing Interests: The authors have declared that no competing interests exist.
Figures
References
- Gatchel JR, Zoghbi HY. Diseases of unstable repeat expansion: Mechanisms and common principles. Nat Rev Genet. 2005;6:743–755.
- Zoghbi HY, Orr HT. Spinocerebellar ataxia type1. Semin Cell Biol. 1995;6:29–35.
- Kish SJ, el-Awar M, Schut L, Leach L, Oscar-Berman M, et al. Cognitive deficits in olivopontocerebellar atrophy: Implication for the cholinergic hypothesis of Alzheimer's dementia. Ann Neurol. 1988;24:200–206.
- Bürk K, Globas C, Bösch S, Klockgether T, Zühlke C, et al. Cognitive deficits in spinocerebellar ataxia type 1, 2, and 3. J. Neurol. 2003;250:207–211.
- Orr HT, Zoghbi HY. SCA1 molecular genetics: A history of a 13 year collaboration against glutamines. Hum Mol Genet. 2001;10:2307–2311.
- Klement IA, Skinner PJ, Kaytor MD, Yi H, Hersch SM, et al. Ataxin-1 nuclear localization and aggregation: Role in polyglutamine-induced disease in SCA1 transgenic mice. Cell. 1998;95:45–53.
- Emamian ES, Kaytor MD, Duvick LA, Zu T, Tousey SK, et al. Serine 776 of ataxin-1 is critical for polyglutamine-induced disease in SCA1 transgenic mice. Neuron. 2003;38:375–387.
- Chen H–K, Fernandez-Funez P, Acevedo SF, Lam YC, Kaytor MD, et al. Interaction of Akt-phosphorylated ataxin-1with 14-3-3 mediates neurodegeneration in spinocerebellar ataxia type 1. Cell. 2003;113:457–468.
- Cummings CJ, Sun Y, Opal P, Antalffy B, Mestril R, et al. Overexpression of inducible Hsp70 chaperone suppresses neuropathology and improves motor function in SCA1 mice. Hum Mol Genet. 2001;10:1511–1518.
- Lin X, Antalffy B, Kang D, Orr HT, Zoghbi HY. Polyglutamine expansion downregulates specific neuronal genes before pathologic changes in SCA1. Nat Neurosci. 2001;3:157–163.
- Carmichael J, Sugars KI, Bao YP, Rubinsztein DC. Glycogen synthase kinase-3beta inhibitors prevent cellular polyglutamine toxicity caused by the Huntington's disease mutation. J Biol Chem. 2002;277:33791–33798.
- Chen G, Zeng W-Z, Yuan P-X, Huang L-D, Jiang Y-M, et al. The mood-stabilizing agents lithium and valproate robustly increase the levels of the neuroprotective protein bcl-2 in the CNS. J Neurochem. 1999;72:879–882.
- Pilcher HR. Drug research: The ups and downs of lithium. Nature. 2003;425:118–120.
- Jope RS. Lithium and GSK-3: One inhibitor, two inhibitory actions, multiple outcomes. Trend Pharmacol Sci. 2003;24:441–443.
- Chen G, Masana MI, Manji HK. Lithium regulates PKC-mediated intracellular cross-talk and gene expression in the CNS in vivo. Bipolar Disord. 2000;2:217–236.
- Phiel CJ, Wilson CA, Lee VM-Y, Klein PS. GSK3α regulates production of Alzheimer's disease amyloid-β peptide. Nature. 2003;423:435–439.
- Chuang D-M, Chen R-W, Chalecka-Franaszek E, Ren M, Hashimoto R, et al. Neuroprotective effects of lithium in cultured cells and animal models of diseases. Bipolar Disord. 2002;4:129–136.
- Watase K, Weeber EJ, Xu B, Antalffy B, Yuva-Paylor L, et al. A long CAG repeat in the mouse Sca1 locus replicates SCA1 features and reveals the impact of protein solubility on selective neurodegeneration. Neuron. 2002;34:905–919.
- Bordi F, Marcon C, Chiamulera C, Reggiani A. Effects of the metabotropic glutamate receptor antagonist MCPG on spatial and context-specific learning. Neuropharmacology. 1996;35:1557–1565.
- Favata MF, Horiuchi KY, Manos EJ, Daulerio EJ, Stradley DA, et al. Identification of a novel inhibitor of mitogen-activated protein kinase kinase. J Biol Chem. 1998;273:18623–18632.
- Hargreaves EL, Cain DP. Hyperactivity, hyper-reactivity, and sensorimotor deficits induced by low doses of the N-methyl-D-aspartate non-competitive channel blocker MK801. Behav Brain Res. 1992;47:23–33.
- Sholl DA. The organization of the visual cortex in the cat. J Anat. 1955;89:33–46.
- Luthi-Carter R, Strand A, Peters NL, Solano MS, Hollingsworth ZR, et al. Decreased expression of striatal signaling genes in a mouse model of Huntington's disease. Hum Mol Genet. 2000;9:1259–1271.
- Chalecka-Franaszek E, Chuang DM. Lithium activates the serine/threonine kinase Akt-1 and suppresses glutamate-induced inhibition of Akt-1 activity in neurons. Proc Natl Acad Sci U S A. 1999;96:8745–8750.
- Beaulieu J-M, Sotnikova TD, Yao W-D, Kockeritz L, Woodgett JR. Lithium antagonizes dopamine-dependent behaviors mediated by an AKT/glycogen synthase kinase 3 signaling cascade. Proc Natl Acad Sci U S A. 2004;101:5099–5104.
- Song L, De Sarno P, Jope RS. Central role of glycogen synthase kinase-3β in endoplasmic reticulum stress-induced caspase-3 activation. J Biol Chem. 2002;277:44701–44708.
- Li X, Bijur GN, Jope RS. Glycogen synthase kinase-3β, mood stabilizers and neuroprotection. Bipolar Disord. 2002;4:137–144.
- Shahbazian MD, Orr HT, Zoghbi HY. Reduction of Purkinje cell pathology in SCA1 transgenic mice by p53 deletion. Neurobiol Dis. 2001;8:974–981.
- Zoghbi HY, Orr HT. Spinocereballar ataxias. In: Scriver CR, Beaudet AL, Sly WS, editors. The metabolic and molecular bases of inherited disease. New York: McGraw-Hill; 2001. pp. 5741–5758.
- Yuan PX, Chen G, Manji HH. Lithium activates the c-Jun NH2-terminal kinases (JNKs) in vitro and in the CNS in vivo. J Neurochem. 1999;73:2299–2309.
- Wood GE, Young LT, Reagan LP, Chen B, McEwen BS. Stress-induced structural remodeling in hippocampus: Prevention by lithium treatment. Proc Natl Acad Sci U S A. 2004;101:3973–3978.
- Magarinos AM, McEwen BS, Flugge G, Fuch E. Chronic psychological stress causes apical dendritic atrophy of hippocampal CA3 pyramidal neurons in subordinate tree shrews. J Neurosci. 1996;16:3534–3540.
- Dixon JF, Hokin LE. Lithium acutely inhibits and chronically up-regulates and stabilizes glutamate uptake by presynaptic nerve endings in mouse cerebral cortex. Proc Natl Acad Sci U S A. 1998;95:8363–8368.
- Son H, Yu IT, Hwang S-J, Kim JS, Lee S-H, et al. Lithium enhances long-term potentiation independently of hippocampal neurogenesis in the rat dentate gyrus. J Neurochem. 2003;85:872–881.
- Chen G, Rajkowska G, Du F, Seraji-Bozorgzad N, Manji HK. Enhancement of hippocampal neurogenesis by lithium. J Neurochem. 2000;75:1729–1734.
- Chaudhuri-Sengupta S, Sarkar R, Maiti BR. Lithium action on adrenomedullary and adrenocortical functions and serum ionic balance in different age groups of albino rats. Arch Physiol Biochem. 2003;111:246–253.
- Lorenzetti D, Watase K, Xu B, Matzuk MM, Orr HT, et al. Repeat instability and motor incoordination in mice with a targeted expanded CAG repeat in the Sca1 locus. Hum Mol Genet. 2000;9:779–785.
- Freeman MP, Freeman SA. Lithium: Clinical considerations in internal medicine. Am J Med. 2006;119:478–481.
- Berger Z, Ttofi EK, Michel CH, Pasco MY, Tenant S, et al. Lithium rescues toxicity of aggregate-prone proteins in Drosophila by perturbing Wnt pathway. Hum Mol Genet. 2005;14:3003–3011.
- Wood NI, Morton AJ. Chronic lithium chloride treatment has variable effects on motor behavior and survival of mice transgenic for the Huntington's disease mutation. Brain Res Bull. 2003;61:375–383.
- Slow EJ, Graham RK, Osmand AP, Devon RS, Lu G, et al. Absence of behavioral abnormalities and neurodegeneration in vivo despite widespread neuronal huntingtin inclusions. Proc Natl Acad Sci U S A. 2005;102:11402–11407.
- Graham RK, Deng Y, Slow EJ, Haigh B, Bissada N, et al. Cleavage at the caspase-6 site is required for neuronal dysfunction and degeneration due to mutant Huntingtin. Cell. 2006;125:1179–1191.
- Watase K, Zoghbi HY. Modelling brain diseases in mice: The challenge of design and analysis. Nat Rev Genet. 2003;4:296–307.
Source: PubMed